Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at D. Boral Capital

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $32.00 target price on the stock.

Several other equities research analysts have also commented on CMPX. Jefferies Financial Group boosted their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Guggenheim began coverage on Compass Therapeutics in a report on Monday, February 24th. They issued a “buy” rating and a $12.00 price target for the company. Finally, Piper Sandler began coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $11.38.

Compass Therapeutics Trading Down 4.5 %

CMPX stock opened at $1.90 on Tuesday. The firm has a 50-day moving average of $2.84 and a two-hundred day moving average of $2.10. The company has a market cap of $262.74 million, a price-to-earnings ratio of -5.13 and a beta of 1.19. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, equities analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. MPM Bioimpact LLC lifted its position in Compass Therapeutics by 51.9% during the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after purchasing an additional 2,926,002 shares during the period. Enavate Sciences GP LLC acquired a new stake in Compass Therapeutics in the fourth quarter worth $11,293,000. Tang Capital Management LLC raised its position in shares of Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after purchasing an additional 4,087,005 shares during the period. Rock Springs Capital Management LP boosted its stake in Compass Therapeutics by 2.7% during the 4th quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company’s stock valued at $8,380,000 after purchasing an additional 150,336 shares during the last quarter. Finally, Blue Owl Capital Holdings LP lifted its stake in Compass Therapeutics by 2.6% during the 4th quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company’s stock valued at $4,284,000 after acquiring an additional 75,000 shares in the last quarter. 68.43% of the stock is owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.